AACR logo

More articles from Drug Design

Abstract LB-A09: EED targeted PROTACs degrade EED, EZH2, and SUZ12 in the PRC2 complex
Jessie Hao-Ru Hsu, Timothy Rasmusson, James Robinson, Fiona Pachl, Jon Read, Sameer Kawatkar, Daniel H O'Donovan, Sharan Bagal, Erin Code, Philip Rawlins, Argyrides Argyrou, Ronald Tomlinson, Ning Gao, Xiahui Zhu, Elisabetta Chiarparin, Kelly Jacques, Minhui Shen, Haley Woods, Emma Bednarski, David M. Wilson, Lisa Drew, M. Paola Castaldi, Stephen Fawell, Andrew Bloecher

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) LB-A09; DOI: 10.1158/1535-7163.TARG-19-LB-A09
Abstract A108: Specific and traceless payload release from HER2-ADC containing LBG-linker prodrug by the action of lysosomal β-glucuronidase
Dong Yeon Shin, Taeik Jang, Ho Young Song, Sung Min Kim, Yun-Hee Park, Chang Sik Park, Hwanhee Oh, Juyuel Baek, Jeiwook Chae, Chang-Sun Lee

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) A108; DOI: 10.1158/1535-7163.TARG-19-A108
Abstract A109: Repurposing low dose of quinoline methanol derivatives as a novel treatment for pediatric glioblastoma
Jian Teng, Litia Carvalho, Elie Tabet, Bakhos Tannous

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) A109; DOI: 10.1158/1535-7163.TARG-19-A109
Abstract A107: Small Molecule Degraders of the Estrogen Receptor (SERDs): Optimization of the tricyclic indole scaffold beyond AZD9496
Bernard Barlaam, Jason Breed, Rodrigo J Carbajo, Eric Gangl, Samantha Hughes, Christopher J Morrow, Thomas A Moss, Radoslaw Polanski, Willem M Nissink, Daniel O'Donovan, Jeffrey Varnes, Bin Yang, James S Scott

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) A107; DOI: 10.1158/1535-7163.TARG-19-A107
Abstract A106: A peptide based on transmembrane domain of S1PR4 as a tumor cell growth inhibitor
Tetsuhiko Yoshida, Kenichi Tanaka, Shuichi Asakawa, Makoto Sawada, Yoshinori Hasegawa, Ikuhiko Nakase, Nahoko Bailey Kobayashi

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) A106; DOI: 10.1158/1535-7163.TARG-19-A106
Abstract A110: Isothiocyanate-containing hybrid androgen receptor (AR) antagonist downregulates AR and induces ferroptosis in GSH–deficient prostate cancer cells
Zhihui Qin, Liping Xu, Siyu Ou

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) A110; DOI: 10.1158/1535-7163.TARG-19-A110
Abstract A112: Drug discovery efforts on the RNA protein methyltransferase METTL3/METTL14
P. Ann Boriack-Sjodin, Alexandra K. Gardino, Thomas A. Wynn, Shane M. Buker, Monique Laidlaw, E. Allen Sickmier, Brian L. Hodous, April W. Case, April E. Greene-Colozzi, Robert A. Copeland, Scott Ribich

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) A112; DOI: 10.1158/1535-7163.TARG-19-A112
Abstract A111: AF8c, a pan-ErbB family inhibitor induces apoptotic cell death by stimulating DR5/Nrf2 via ROS in colorectal cancer cells
Soyeon Jeong, Ahmed Karam Farag, Hye Kyeong Yun, Yoon A Jeong, Dae Yeong Kim, Min Jee Jo, Seong Hye Park, Bo Ram Kim, Jung Lim Kim, Dae-Hee Lee, Eun Joo Roh, Sang Cheul Oh

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) A111; DOI: 10.1158/1535-7163.TARG-19-A111
Abstract A124: Discovery of the clinical candidate AZD1390: a high-quality, potent, and selective inhibitor of ATM kinase with the ability to cross the blood-brain barrier
Kurt G. Pike

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) A124; DOI: 10.1158/1535-7163.TARG-17-A124
Abstract A125: Fragment-based approach to develop small-molecule STAT3 transcription factor inhibitors
Kazi S. Nahar, Shirin Jamshidi, David E. Thurston, Khondaker Miraz Rahman

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) A125; DOI: 10.1158/1535-7163.TARG-17-A125

Main menu

User menu

Search

More articles from Drug Design

Pages

Articles

Info for

About MCT